UK Risks Becoming a ‘Second-Tier’ Nation for Medical Innovation

The United Kingdom risks being relegated to a “second-tier” nation for medical innovation as a direct result of government policies that are discouraging investment from the world’s leading pharmaceutical companies. A string of corporate pullbacks has raised fears that the country is losing its place at the top table of global life sciences.
This slide down the ranks is being driven by an environment that a top executive has called “terrible” for selling medicines. The UK’s spending on new treatments is significantly lower than that of its peers in Europe and the US. This, combined with outdated pricing rules and high revenue clawbacks, makes it a less prioritized market.
The consequences are clear: companies are choosing to invest elsewhere. MSD’s £1bn London hub has been scrapped. Eli Lilly’s lab is on hold as it builds facilities in China and the US. Sanofi has cut its UK trials by half. These are the actions of companies that no longer see the UK as a first-tier location for growth.
To avoid this fate, a fundamental policy shift is required. The industry is calling for a government plan to align the UK’s commercial terms with those of other leading nations. Without this, the UK’s scientific prowess alone will not be enough to prevent its slide into the second division.